Mechanisms of tumor cell resistance to the current targeted-therapy agents

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Chemotherapy resistance, mediated by factors like multidrug resistance proteins and ATP-binding cassette transporters, poses a significant challenge in cancer treatment.
• Targeted-based cancer therapies (TBCT), including small molecule inhibitors and monoclonal antibodies, offer improved specificity and reduced side effects compared to traditional chemotherapy.
• Despite their advantages, both chemotherapy and TBCT are subject to natural and acquired resistance, necessitating the exploration of novel therapeutic strategies.

Purpose of the Study:

• To review the diverse mechanisms underlying tumor cell resistance to conventional chemotherapy agents.
• To elucidate the resistance mechanisms associated with current targeted-based cancer therapies.
• To provide a foundation for developing improved and novel cancer treatment modalities by understanding resistance pathways.

Main Methods:

• Literature review of existing research on cancer drug resistance.
• Analysis of molecular mechanisms of resistance to chemotherapy.
• Examination of resistance pathways associated with targeted therapies.

Main Results:

• Multidrug resistance proteins and ATP-binding cassette transporters contribute to chemotherapy efflux and resistance.
• Tumor cells develop resistance to targeted therapies, diminishing their clinical efficacy.
• A comprehensive understanding of these resistance mechanisms is essential for therapeutic advancement.

Conclusions:

• Resistance to both chemotherapy and targeted therapies remains a critical obstacle in oncology.
• Further research into the intricate mechanisms of drug resistance is vital for the development of next-generation cancer treatments.
• Identifying and overcoming resistance pathways will pave the way for more effective and durable cancer therapies.